Talquetamab
- Generic Name
- Talquetamab
- Brand Names
- Talvey
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2226212-40-2
- Unique Ingredient Identifier
- 4W3KFI3TN3
- Background
Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple...
- Indication
In the US, talquetamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In Europe, talquetamab is indicated in patients who received at least three prior therap...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- 🇪🇸
Hosp Clinico Univ de Salamanca, Salamanca, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
🇺🇸City of Hope, Duarte, California, United States
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06550895
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- North Estonia Medical Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06505369
- Locations
- 🇳🇴
Oslo University Hospital, Oslo Myeloma Centre, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇩🇰Vejle hospital, Vejle, Denmark
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06500884
- Locations
- 🇺🇸
Icahn School of Medicine at Mt. Sinai, New York, New York, United States
🇧🇷Instituto D Or de Pesquisa e Ensino IDOR, Sao Paulo, Brazil
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT06461988
- Locations
- 🇺🇸
New Mexico Cancer Research Alliance, Albuquerque, New Mexico, United States
🇺🇸Stanford University, Palo Alto, California, United States
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06353022
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
🇫🇷CH Lyon Sud, Lyon, France
🇫🇷CH de la Côte Basque, Bayonne, France
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
🇮🇱Carmel Medical Center, Haifa, Israel
Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Carl Ola Landgren, MD, PhD
- Target Recruit Count
- 50
- Registration Number
- NCT06100237
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT06066346
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05972135
- Locations
- 🇺🇸
Texas Oncology, Austin, Texas, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.